Duke Dialogues at PAS: A discussion about clinical management at sites with consistently high rates of survival without BPD
Approximately 17,500 premature infants develop BPD each year in the US. Although rare in the general population, BPD is the most common pulmonary morbidity associated with prematurity and the incidence is increasing.
There are no FDA indicated therapies that prevent BPD or are available to treat BPD symptoms. To date, only vitamin A and caffeine prevent BPD without known significant long term adverse events. Postnatal steroids reduce BPD, but increase the risk of cerebral palsy.38,39 Although inhaled nitric oxide is beneficial in term infants with hypoxic respiratory failure, the majority of studies demonstrate that it does not prevent BPD in premature infants, although there was a great deal of heterogeneity in the patient populations, dose, and duration of inhaled nitric oxide. One problem with the vast majority of trials of drugs tested to prevent BPD is that they did not establish the safety, preliminary effectiveness, PK, pharmacodynamics, or dose prior to implementation of phase III randomized, controlled trials.
Characterize epidemiology of BPD in premature infants. Discuss evolving risk of BPD in the Duke cohort.
Present rationale for observed efficacy of treatment strategies associated with decreased risk of BDP in premature infants at the Duke site.
Summarize the current landscape of clinical drug trials for the prevention or treatment of BPD in premature infants
- 1.00 ANCC
- 1.00 Attendance
- 1.00 JA Credit